Stocks & Investing
Fri, September 6, 2024
Thu, April 11, 2024
[ 12:00 AM ] - WOPRAI
Fri, March 8, 2024
Fri, October 20, 2023
[ 12:00 AM ] - WOPRAI
Tue, November 15, 2022
[ 12:00 AM ] - WOPRAI
Mon, November 14, 2022
[ 12:00 AM ] - WOPRAI
Mon, October 17, 2022
[ 12:00 AM ] - WOPRAI
Fri, September 30, 2022
[ 12:00 AM ] - WOPRAI
Fri, July 29, 2022
Mon, June 13, 2022
Tue, March 2, 2021
[ 12:00 AM ] - WOPRAI
Fri, October 16, 2020
[ 12:00 AM ] - WOPRAI
Tue, May 19, 2020
Thu, December 12, 2019
[ 12:00 AM ] - WOPRAI
Tue, November 12, 2019
Fri, September 6, 2019
[ 12:00 AM ] - WOPRAI
Mon, May 13, 2019
Fri, May 3, 2019
Mon, October 8, 2018
[ 12:00 AM ] - WOPRAI
Fri, June 15, 2018
[ 12:00 AM ] - WOPRAI
Mon, November 13, 2017
Fri, January 20, 2017
Mon, August 3, 2015
Tue, March 17, 2015
[ 12:00 AM ] - WOPRAI
Thu, March 5, 2015
[ 12:00 AM ] - WOPRAI
Mon, November 3, 2014
[ 12:00 AM ] - WOPRAI
Mon, July 28, 2014
[ 12:00 AM ] - WOPRAI
Tue, June 10, 2014
[ 12:00 AM ] - WOPRAI
Fri, April 4, 2014
[ 12:00 AM ] - WOPRAI
Fri, March 14, 2014 Chris Schott Upgraded (AMRX) to Hold and Held Target at $9 on, Sep 6th, 2024
Chris Schott of JP Morgan, Upgraded "Amneal Pharmaceuticals, Inc." (AMRX) to Hold and Held Target at $9 on, Sep 6th, 2024.
Chris has made no other calls on AMRX in the last 4 months.
There are 3 other peers that have a rating on AMRX. Out of the 3 peers that are also analyzing AMRX, 0 agree with Chris's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Chris
- Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $10 on, Tuesday, August 13th, 2024
- Les Sulewski of "Truist Securities" Maintained at Strong Buy with Increased Target to $10 on, Monday, August 12th, 2024
- Nathan Rich of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $8 on, Monday, May 6th, 2024
